New injectable drug hopes to boost heart function in PAH patients

NCT ID NCT07177703

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding an injectable medication called treprostinil to standard oral therapy can improve heart function in people with intermediate-risk pulmonary arterial hypertension (PAH). About 32 adults will receive the drug for 3 months, with heart scans and walking tests used to measure progress. The goal is to see if the treatment helps the right side of the heart pump more blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Treprostinil (injectable medication)
What this could lead to: If it works, this could offer a new treatment option for people with intermediate-risk PAH whose current oral medications aren't enough.
What could go wrong: This is a small, early-phase study with no placebo group, so results may not be conclusive. The injectable drug can cause side effects like pain at the injection site and requires careful dose adjustment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION (PAH)

More trials for these conditions

Other studies related to the condition(s) this trial covers.